IRIS
PATRIARCA, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.160
EU - Europa 2.680
AS - Asia 734
Continente sconosciuto - Info sul continente non disponibili 14
AF - Africa 9
OC - Oceania 4
SA - Sud America 2
Totale 14.603
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.106
UA - Ucraina 1.054
CN - Cina 431
DE - Germania 407
IT - Italia 349
FI - Finlandia 315
SE - Svezia 227
IE - Irlanda 198
SG - Singapore 88
TR - Turchia 78
VN - Vietnam 69
CA - Canada 53
GB - Regno Unito 51
IN - India 35
BE - Belgio 20
IR - Iran 17
RU - Federazione Russa 17
EU - Europa 14
FR - Francia 10
NL - Olanda 10
TG - Togo 8
CZ - Repubblica Ceca 7
JP - Giappone 7
AU - Australia 4
RO - Romania 4
RS - Serbia 4
KR - Corea 3
BR - Brasile 2
CH - Svizzera 2
HK - Hong Kong 2
IL - Israele 2
TW - Taiwan 2
AT - Austria 1
BG - Bulgaria 1
DK - Danimarca 1
EG - Egitto 1
LU - Lussemburgo 1
MX - Messico 1
PT - Portogallo 1
Totale 14.603
Salva come PNG Salva come JPEG
Città #
Fairfield 1.589
Woodbridge 1.361
Houston 993
Ann Arbor 893
Ashburn 736
Jacksonville 700
Wilmington 644
Seattle 633
Chandler 569
Cambridge 509
Dearborn 454
Boardman 268
Princeton 211
Beijing 208
Dublin 198
Udine 146
San Diego 99
Izmir 78
Dong Ket 69
Singapore 60
Ogden 51
Des Moines 44
Norwalk 43
Ottawa 39
Hefei 33
Kunming 26
Nanjing 26
Redmond 19
Trieste 19
Brussels 18
Nanchang 15
Dallas 14
Guangzhou 13
Hyderabad 13
New York 13
Simi Valley 13
Rome 12
Duino-Aurisina 11
Shenyang 11
Toronto 11
Chengdu 10
Council Bluffs 10
Leawood 10
Falls Church 9
Fuzhou 9
Redwood City 9
Venezia 9
Jinan 8
Lomé 8
Los Angeles 8
Uppsala 7
Washington 7
Andover 6
Grafing 6
Munich 6
San Mateo 6
Zhengzhou 6
Helsinki 5
Indiana 5
Lappeenranta 5
Phoenix 5
Wuhan 5
Belgrade 4
Brno 4
Changsha 4
Chongqing 4
Fayetteville 4
Frankfurt am Main 4
Hebei 4
Milan 4
Mumbai 4
Sacramento 4
Zanjan 4
Amsterdam 3
Augusta 3
Edinburgh 3
Fiumicino 3
Lucca 3
Monmouth Junction 3
Ningbo 3
Olomouc 3
Pordenone 3
Shenzhen 3
Tappahannock 3
Verona 3
Ardabil 2
Bologna 2
Cadoneghe 2
Cameri 2
Clifton 2
Cossato 2
Eindhoven 2
Hangzhou 2
Hong Kong 2
Horia 2
Jena 2
Jerusalem 2
Jiaxing 2
Loiano 2
Melbourne 2
Totale 11.131
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy 233
Combined orthotopic heart transplantation followed by autologous stem cell transplantation in a patient with light chain amyloidosis and isolated cardiac involvement 162
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 144
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 141
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation 138
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). 133
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 133
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 129
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 128
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. 125
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 125
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 123
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 120
Clinical feature and outcome in seven patients wuth hyaline or mixed variant of Castleman’s disease. A single centre experience 119
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 119
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 117
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 116
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” 115
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. 115
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 115
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 113
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 113
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease 111
CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide 111
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation 110
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 109
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 109
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. 108
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability 108
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 105
Rituximab for the treatment of type II mixed cryoglobulinemia 104
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) 103
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. 103
A comparison of allografting with autografting for newly diagnosed myeloma 102
Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant patients: intercontinental prospective study of Infectious Diseases Working Party of the European Bone Marrow Transplantation group 102
Defibrotide : review on clinical use and future development 101
Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon. 101
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. 101
Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors. 100
Flow cytometry evaluation of plasma cells contaminating leukapheresis pre- and post- CD34-positive selection- 99
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. 99
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. 99
Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma 99
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 97
Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy. 95
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 95
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 94
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 94
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 93
JAK-2 inhibitors and allogeneic transplant in myelofibrosis 92
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 92
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group 92
Acute myeloid leukemia following chronic low-dose cyclophosphamide in metastatic breast cancer 91
Cytokines dysregulation and chronic graft versus host disease after allogeneic haematopoieitc stem cell transplantation with reduced intensity conditioning 91
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) 91
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib 91
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) 89
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey in 50 patients 89
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 89
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 88
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous: a retrospective study based on the time of HLA typing and donor availability 88
Multiple Myeloma: presenting features and survival according to hospital referral 87
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. 87
‘Real-life’ report on the management of chronic GvHD in the gruppo Italiano trapianto midollo osseo (GITMO) 87
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 85
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation 85
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients 84
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study 84
FEASIBILITY AND OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 60 YEARS WITH POOR RISK ACUTE MYELOID LEUKEMIA 83
Treatment of refractory chronic GVHD with rituximab: a GITMO study 83
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. 82
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation 82
Sequential study of cytokine and lymphocyte patterns in patients with chronic agraft versus host disease after reduced intensity conditioning allogenic stem cell transplantation 79
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 79
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 79
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. 79
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. 79
Pseudomonas pickettii (Biovar VA-II): a rare cause of bacteremias in haematologic patients. 78
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study 78
Efficacy of tuemor necrosis factor alfa blockade with infliximab for the treatment of svere steroid-refractory acute graft versus host disease. 78
Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant 78
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 77
Autologous transplantation and maintenance therapy in multiple myeloma 77
Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. 76
Non-myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo 75
The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma. 75
Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). 75
Allogeneic stem cell transplantation and novel therapies: is the treatment paradigm for younger patients with chronic lymphocytic leukemia changing? 75
The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo 75
Qualitative and quantitative polymerase chain reaction monitoring minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation . 75
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 75
Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment 74
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. 74
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation 74
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation 74
Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the G.I.T.M.O. Experience. 74
High dose therapy with stem cell rescue in elderly atients with aggressive poor risk lymphomas: a review of 14 cases. 73
Feasibility of autologous stem cell transplantation in chronic carriers of hepatitis B and hepatitis C virus 73
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. 73
Long lasting remission after haploidentical stem cell transplant and pre-emptive donor lymphocyte infusions in a patient with primary refractory Hodgkin lymphoma 73
Totale 9.764
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.670
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.670
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.939 0 0 162 642 322 707 499 529 333 354 101 290
2020/20212.689 50 294 71 393 74 354 234 328 317 104 288 182
2021/20221.611 68 205 85 102 37 69 101 77 15 269 328 255
2022/20231.465 224 73 13 177 142 428 1 103 220 17 32 35
2023/2024489 64 28 10 17 67 53 25 43 81 46 26 29
2024/2025371 86 285 0 0 0 0 0 0 0 0 0 0
Totale 15.192